Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor

Summary Background Data on combination‐biologic treatment in (IBD) are still scant. Aim To explore outcomes of patients co‐exposed to anti‐TNF and vedolizumab. Methods Patients starting vedolizumab having measurable anti‐TNF levels after recently stopping adalimumab/infliximab (‘VDZ‐aTNF’ group), we...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Alimentary pharmacology & therapeutics 2018-04, Vol.47 (8), p.1117-1125
Hauptverfasser:	Ben‐Horin, S., Ungar, B., Kopylov, U., Lahat, A., Yavzori, M., Fudim, E., Picard, O., Peled, Y., Eliakim, R., Del Tedesco, E., Paul, S., Roblin, X.
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical trials Corticosteroids Exposure Immunological memory Infliximab Lymphocytes Lymphocytes T Memory cells Monoclonal antibodies Patients Pharmacokinetics Remission Tumor necrosis factor-TNF Tumor necrosis factor-α Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!